Uppsala, Sweden – December 20, 2013 – Orexo AB , “Orexo” (OTCQX: ORXOY; NASDAQ OMX Stockholm: ORX) announces adjustment to earlier communicated EBIT expectations for Q4 2013 with continuation of current conservative revenue recognition practise. Since launch of Zubsolv® in US, Orexo has supplied US wholesalers with products at a total value of close to USD 11 million . As the launch of Zubsolv is still in an early phase, Orexo has decided to continue with its current conservative revenue recognition practice, which is based on actual patient demand for Zubsolv, and not switch to a revenue recognition model based on supplies to wholesaler. On that basis, only approximately 1/3 of the USD 11 million is expected to be recognized as gross revenue before rebates and other deductions in 2013. Based on this, the earlier communicated expectation to deliver a positive EBIT for Q4 is now replaced by an expectation of a negative EBIT of about SEK -30 million for the quarter. Zubsolv demand continues the positive week over week volume share growth. Current market share is now approaching 2% of the buprenorphine/naloxone market in the US according to Wolters Kluwer statistics. For further information, please contact: Nikolaj SØrensen, President and CEO Henrik Juuel , EVP and Chief Financial Officer Tel: +46 18-780 88 00, E-mail: firstname.lastname@example.org About Orexo AB Orexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology and commercial operations in the United States . The company is commercializing its proprietary product, Zubsolv®, for maintenance treatment of opioid dependence, in the United States . Zubsolv is a novel formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU and US. Orexo AB , with its headquarters in Sweden , is listed on NASDAQ OMX Stockholm Exchange, under the symbol “ORX”, and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace in the U.S. under the symbol “ORXOY”. The largest shareholders are Novo A/S and HealthCap. For information about Orexo AB , please visit www.orexo.com . Orexo AB (publ) discloses the information provided herein pursuant to the Financial Instruments Trading Act and/or the Securities Markets Act. The information was submitted for publication at 08:45 am CET on December 20, 2013 . This information was brought to you by Cision http://news.cision.com http://news.cision.com/orexo/r/orexo-adjusts-ebit-expectations-for-q4--2013,c9515421 The following files are available for download: http://mb.cision.com/Main/694/9515421/196021.pdf
Most Popular Stories
- Apple, HP, Intel May Take a Hit from Slowdown in Smartphone Sales Growth
- FDIC Files Lawsuit on Behalf of Banks Allegedly Hurt by Libor Scandal
- Some California Cities Seeking Water Independence
- Motley Crue's Nikki Sixx Marries Model Courtney Bingham
- Chinese e-Commerce Giant Alibaba Gears for IPO in U.S.
- Will Missing Malaysian Jet Prompt Aviation System Change?